WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014177271) TARGETING O-ACETYLATED GD2 GANGLIOSIDE AS A NEW THERAPEUTIC AND DIAGNOSTIC STRATEGY FOR CANCER STEM CELLS CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/177271    International Application No.:    PCT/EP2014/001142
Publication Date: 06.11.2014 International Filing Date: 29.04.2014
IPC:
C07K 16/30 (2006.01)
Applicants: OGD2 PHARMA [FR/FR]; 3, chemin du Pressoir Chênaie 44100 Nantes (FR).
UNIVERSITÉ DE NANTES [FR/FR]; 1, quai de Tourville, BP 13522 F-44035 Nantes Cedex 1 (FR)
Inventors: BIRKLE, Stéphane; (FR).
COCHONNEAU, Denis; (FR).
DORVILLIUS, Mylène; (FR).
LE DOUSSAL, Jean-Marc; (FR).
TERME, Mickaël; (FR)
Agent: BARBOT, Willy; SIMODORO Parc Cézanne II - Bat. G 290 avenue Galilée 13857 Aix-en-Provence Cedex 3 (FR)
Priority Data:
13002268.4 29.04.2013 EP
Title (EN) TARGETING O-ACETYLATED GD2 GANGLIOSIDE AS A NEW THERAPEUTIC AND DIAGNOSTIC STRATEGY FOR CANCER STEM CELLS CANCER
(FR) CIBLAGE DU GANGLIOSIDE GD2 O-ACÉTYLÉ COMME NOUVELLE STRATÉGIE THÉRAPEUTIQUE ET DIAGNOSTIQUE DANS LE CANCER À CELLULES SOUCHES TUMORALES
Abstract: front page image
(EN)The present disclosure relates to an antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer. The present disclosure further concern a pharmaceutical composition comprising said antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, said method comprising administering said antibody to said patient. The present disclosure also relates to a method for diagnosing a CSC and to the use of the 0-acetylated-GD2 ganglioside as a biomarker of CSC cancer. Finally, the disclosure relates to a method for predicting the response of a subject affected with CSC cancer to a treatment with an antibody or a composition of the invention.
(FR)L'invention porte sur un anticorps qui reconnaît le ganglioside gd2 o-acétylé, lequel anticorps est destiné au traitement du cancer à cellules souches tumorales (CST). L'invention se rapporte en outre à une composition pharmaceutique renfermant ledit anticorps qui est destinée au traitement d'un cancer CST, et à un procédé permettant de traiter un cancer CST chez un patient qui en a besoin, lequel procédé consiste à administrer ledit anticorps audit patient. L'invention concerne aussi un procédé de diagnostic d'un cancer CST et l'utilisation du ganglioside gd2 o-acétylé comme biomarqueur d'un cancer CST. Enfin, l'invention porte sur un procédé qui permet de prédire la réponse d'un sujet atteint d'un cancer CST à un traitement par un anticorps ou une composition selon l'invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)